Optimal treatment of early stage breast cancer remains an active area of study.
An expert multidisciplinary committee reviewed clinical data on systemic therapy for early stage, stage I and II breast cancer.
Guidelines for treatment were developed for Texas Oncology, P.A., the largest private practice group of oncologists in the United States.
This group of physicians treats approximately 5000 new breast cancer patients each year and has a major impact on oncology care in the state of Texas.
These guidelines identify prognostic factors which help the practitioner in choosing treatment for patients.
Subsets of patients are identified for whom no systemic therapy is warrented.
Standard chemotherapy and hormonal therapy regimens are outlined for patients with early stage disease at increased risk for relapse.
Dose intensification for high risk stage II patients is reviewed.
Timing of therapy and the sequencing of chemotherapy and radiation therapy is addressed.
Strategies for the follow-up of patients with a history of breast cancer are outlined.
Mots-clés Pascal : Recommandation, Conférence consensus, Article synthèse, Chimiothérapie, Dose forte, Traitement, Anticancéreux, Radiothérapie, Tumeur maligne, Glande mammaire, Stade précoce, Homme, Texas, Etats Unis, Amérique du Nord, Amérique, Toxicité, Pronostic, Glande mammaire pathologie, Intensification
Mots-clés Pascal anglais : Recommendation, Consensus conference, Review, Chemotherapy, High dose, Treatment, Antineoplastic agent, Radiotherapy, Malignant tumor, Mammary gland, Early stage, Human, Texas, United States, North America, America, Toxicity, Prognosis, Mammary gland diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0308829
Code Inist : 002B02R02. Création : 15/07/1997.